A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation
Chunying Ma,
Miao Chen,
Weiming Chu,
Jiayi Tao,
Delong Kong,
Mengmeng Zhang,
Wenhua Feng
Affiliations
Chunying Ma
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Miao Chen
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Weiming Chu
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Jiayi Tao
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Delong Kong
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Mengmeng Zhang
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Wenhua Feng
Department of New Drug Research and Development, Institute of Materia Medical, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing’s disease and acromegaly. The liquid-phase total synthesis of pasireotide-a 18-membered cyclic hexapeptide-was achieved by the 3 + 2 + 1 strategy, and the Pro1-Phe6 peptide bond was selected as the final cyclization position. Two key fragments were simply synthesized using N,O-bis(trimethylsilyl)acetamide/N-hydroxysuccinimide ester (BSA/NHS) as coupling agents, and processes of the two key fragments were simple without any chromatographic purification. The current synthesis method is easily scalable and produces the target peptide with an overall yield of 15%.